As speculation swirled regarding Donald Trump’s health, the White House firmly denied rumors suggesting that the former president was either hospitalized or deceased. This development comes amid ongoing scrutiny of Trump’s health, particularly as he approaches the age of 79. Prior to these rumors, Trump had been actively engaging with the public, conducting numerous news conferences just the week before the speculation intensified.

The decisive moment came when the White House announced that Trump would not be making any public appearances for the day, which fueled online chatter about his wellbeing. This announcement was met with immediate backlash from Trump’s team, who emphasized that he had been working nonstop during the Easter weekend. White House communications stated, “Fear not! President Trump literally never stops working,” reinforcing the narrative that he was in good health.

Despite these reassurances, concerns about Trump’s health have been exacerbated by visible signs of distress, including bruising on his hands and skin flare-ups. These symptoms have been attributed to frequent handshaking and high doses of aspirin, as well as a diagnosis of chronic venous insufficiency, a benign age-related condition causing leg swelling. The White House has repeatedly dismissed these health concerns, insisting that Trump remains fit for duty.

Historically, Trump’s most significant health scare occurred in October 2020 when he tested positive for COVID-19. During that hospitalization, his blood oxygen levels dropped into the 80s, raising alarms about his condition. He spent three nights at Walter Reed National Military Medical Center before returning to the White House. This past experience has led to heightened sensitivity regarding his health, especially given the current rumors.

Trump’s spokesman, Steven Cheung, reiterated the former president’s commitment to his work, stating, “There has never been a President who has worked harder for the American people than President Trump.” This statement reflects the ongoing narrative that Trump is actively engaged in political activities despite the health rumors. However, the absence of public appearances for 12 hours has left some questioning the state of his health.

In response to the swirling rumors, Trump himself addressed the speculation, saying, “I have heard it’s sort of crazy, but last week I did numerous news conferences, all successful.” His remarks aimed to quell fears and assert his vitality, yet the visible signs of health issues have left many unconvinced. The current rumors appear to be largely fueled by social media chatter, lacking any substantial evidence of hospitalization or medical emergencies.

Experts have weighed in on the situation, noting that while Trump’s age and past health issues warrant attention, the current rumors may be exaggerated or unfounded. Karoline Leavitt, a spokesperson for Trump, labeled the speculation as “made-up” and “baseless,” attributing it to political adversaries. As the situation unfolds, the White House continues to maintain that Trump is in good health, though details remain unconfirmed regarding the exact cause of his visible bruising and skin issues.

As the public awaits further updates, the narrative surrounding Donald Trump’s health remains a focal point of discussion. The interplay between political activity and health scrutiny will likely continue to shape perceptions of the former president as he navigates this latest wave of rumors.

The post Donald Trump Dead? Health Rumors and Official Denials appeared first on cottenhamnews.

The cicada COVID variant, known scientifically as BA.3.2, presents a significant public health concern as it spreads across the United States. This highly mutated variant has been detected in at least 25 states as of February 11, 2026, and poses potential challenges to existing immunity from vaccines and prior infections. The variant’s ability to evade immune responses could complicate ongoing efforts to control the pandemic.

BA.3.2 was first identified in South Africa in November 2024 and has since been reported in at least 23 countries. The variant is characterized by an alarming 70 to 75 mutations in its spike protein, which may enable it to circumvent the immune system’s defenses. According to Andrew Pekosz, Ph.D., “It has a lot of mutations that may cause it to look different to your immune system,” highlighting the variant’s potential to evade recognition by the body’s immune response.

Despite these concerns, experts have noted that there is currently no evidence indicating that BA.3.2 is causing more severe disease or higher rates of hospitalization in regions where it is prevalent. Dr. Adolfo García-Sastre stated, “There’s no evidence that BA.3.2 is causing more severe disease or hospitalizations in countries where it’s more widespread,” suggesting that while the variant is concerning, its immediate impact on health outcomes may not be as dire as initially feared.

Furthermore, health officials are monitoring the situation closely. The World Health Organization classified BA.3.2 as a “variant under monitoring” in December 2025, reflecting the need for ongoing surveillance and research. The CDC is also tracking the variant’s spread, with reports indicating that 11% of wastewater samples collected during the week ending March 21, 2026, contained BA.3.2, underscoring its increasing prevalence.

Common symptoms associated with BA.3.2 include cough, fever or chills, sore throat, congestion, shortness of breath, loss of smell or taste, fatigue, headache, and gastrointestinal issues such as diarrhea or vomiting. These symptoms are similar to those of other COVID-19 variants, making it crucial for individuals to remain vigilant and seek testing if they exhibit any signs of illness.

Experts remain cautiously optimistic about the effectiveness of existing vaccines against BA.3.2. Dr. Amesh A. Adalja noted, “The existing vaccine is likely to protect against what matters most: serious illness,” suggesting that while the variant may evade some immune responses, the vaccines could still offer substantial protection against severe outcomes. However, uncertainties persist regarding the overall efficacy of vaccines against this variant.

Details remain unconfirmed regarding the exact impact of BA.3.2 on disease severity and the reasons for its resurgence. As the situation evolves, health authorities continue to assess the variant’s implications for public health and vaccination strategies. The ongoing research will be critical in determining how best to respond to this emerging threat.

The post Cicada COVID Variant BA.3.2 Raises Concerns in the United States appeared first on cottenhamnews.

As the world grappled with COVID-19, expectations were set around the efficacy of vaccines and the control of emerging variants. Prior to the emergence of the Cicada variant, designated BA.3.2, the focus was primarily on the Omicron lineage, which had already demonstrated significant mutations but was manageable with existing vaccines. The UK, like many other countries, had seen a decline in severe cases and hospitalizations, leading to a sense of cautious optimism.

However, the landscape shifted dramatically with the detection of the Cicada variant in South Africa in November 2024. By March 2026, it had spread to 24 countries, including the UK, raising alarms among health officials. The variant carries 70 to 75 genetic changes in its spike protein, which are significant enough to potentially reduce the effectiveness of current vaccines. This marked a decisive moment in the ongoing battle against COVID-19, as the variant began to account for approximately 30% of COVID-19 sequences reported in Denmark, Germany, and the Netherlands from November 2025 to January 2026.

The immediate effects of the Cicada variant’s emergence have been felt across healthcare systems. Symptoms associated with the variant include a particularly painful sore throat, fever, cough, fatigue, and nasal congestion. While the variant has not been shown to cause more severe disease than previous variants, the potential for increased transmission and the strain on healthcare resources during the 2024-25 respiratory virus season remains a concern. Estimates suggest that hospitalizations could range from 390,000 to 550,000, with deaths estimated between 45,000 and 64,000.

Experts have voiced their concerns regarding the implications of the Cicada variant. Kyle B. Enfield noted, “Because it’s significantly different, the current COVID-19 vaccine may not be as effective.” Ian Budd emphasized the importance of the variant’s mutations, stating, “What’s different about it is the number of mutations it carries, particularly on the part of the virus that attaches to your cells.” This highlights the ongoing challenge of vaccine adaptation in the face of rapidly evolving variants.

The Centers for Disease Control and Prevention (CDC) has warned that the Cicada strain “could be associated with seasonal increases in COVID-19 activity,” indicating that public health measures may need to be revisited to mitigate its spread. Despite these concerns, there is currently no evidence suggesting that the Cicada variant causes more severe disease than its predecessors, which offers a glimmer of hope amidst rising case numbers.

As of now, the exact impact of the Cicada variant on public health remains unclear due to limited genomic detection and surveillance capacities in many countries. Additionally, the long-term effectiveness of current vaccines against the Cicada variant is uncertain. Details remain unconfirmed.

In conclusion, the emergence of the Cicada variant BA.3.2 in the UK represents a new chapter in the COVID-19 pandemic, necessitating vigilance and adaptability from health authorities and the public alike. The situation continues to evolve, and ongoing monitoring will be crucial in understanding the full implications of this variant on global health.

The post Covid 19 cicada variant uk: COVID-19 Cicada Variant UK: A New Challenge Emerges appeared first on cottenhamnews.

The BA.3.2 variant, nicknamed Cicada, is spreading quickly across the United States, having been detected in 29 states and 23 countries as of February 2026. First identified in Africa in November 2024, this variant carries between 70 to 75 genetic changes in its spike protein, raising concerns about its potential to evade immunity from previous infections and current vaccines.

Current COVID-19 vaccines may not be as effective against BA.3.2 due to these mutations. Experts have expressed that while there is no evidence that BA.3.2 causes more severe disease than previous variants, the variant may infect people more widely due to immune evasion. Emily Ronay Johnston, a public health expert, stated, “There’s no sign so far that BA.3.2, nicknamed Cicada, is any more dangerous or causes more severe disease than the variants that were circulating in the winter of 2025-26.”

Despite the variant’s rapid spread, COVID-19 still causes between 300-500 deaths per week in the U.S., indicating that the virus continues to pose a significant public health challenge. The first U.S. case of BA.3.2 was detected in a traveler in June 2025, marking the beginning of its presence in the country.

Symptoms associated with the Cicada variant include cough, extreme fatigue, runny nose, headache, sore throat, mild fever, generalized muscle and joint pain, loss of taste or smell, night sweats, and rash. The large majority of people with this variant report that it is a relatively mild illness, especially among those who are vaccinated.

Experts state there is no cause for panic, even as COVID-19 has settled into a manageable seasonal pattern. However, due to the high number of mutations, there is concern that the variant may more easily bypass immunity from previous infections or current vaccines. The immune response against BA.3.2 is notably weaker compared to other dominant strains like XFG.

Historically, BA.3.2 is descended from the Omicron variant, which emerged in late 2021. This lineage has shown a pattern of rapid mutation and adaptation, which has been a hallmark of the virus’s evolution throughout the pandemic.

Details remain unconfirmed regarding the long-term impact of the BA.3.2 variant on public health and the effectiveness of current vaccines against it. As health officials continue to monitor the situation, the focus remains on vaccination efforts and public health measures to mitigate the spread of this new variant.

The post Covid 19 cicada variant: COVID-19 Cicada Variant Spreads Rapidly Across the U.S. appeared first on cottenhamnews.